Clinical Trial Update: Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS [Phase 2]

View source ↗

Summary

Phase 2 efficacy study evaluating lenalidomide (Revlimid) with low-dose continuous melphalan for high-risk myelodysplastic syndromes, including chronic myelomon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Melphalan (Melphalan)
• Revlimid (lenalidomide)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Status: COMPLETED